A Phase 3, Randomized, Placebo-controlled, Double-blind, Phosphate Binder-combination Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis
Latest Information Update: 12 Jan 2026
At a glance
- Drugs TS-172 (Primary)
- Indications Hyperphosphataemia
- Focus Registrational; Therapeutic Use
- Sponsors Taisho Pharmaceutical
Most Recent Events
- 09 Jan 2026 Status changed from not yet recruiting to recruiting.
- 22 Dec 2025 New trial record